Krystal Biotech Inc Revenue Growth Rates (KRYS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Krystal Biotech Inc   (NASDAQ: KRYS)
 

KRYS's Revenue Growth by Quarter and Year

Krystal Biotech Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KRYS/growth
https://api.csimarket.com/api/v1/companies/KRYS/fundamentals
https://api.csimarket.com/api/v1/companies/KRYS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KRYS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 127.34
2nd Quarter June 119.22
1st Quarter March 116.36
FY 362.92

KRYSs Annual Revenue
Krystal Biotech Inc 's Revenue in the fiscal year 2025 $ 389.13 millions
Krystal Biotech Inc 's Revenue in the fiscal year 2024 $ 290.52 millions
Krystal Biotech Inc 's Revenue in the fiscal year 2023 $ 50.70 millions
Krystal Biotech Inc 's Revenue in the fiscal year 2021 $ -72.00 millions
Krystal Biotech Inc 's Revenue in the fiscal year 2020 $ -0.03 millions




KRYS Revenue third quarter 2026 Y/Y Growth Comment
Krystal Biotech Inc reported Revenue improvement of 30.21% year on year in the third quarter 2026, to $ 127.34 millions, this is lower than Krystal Biotech Inc 's recent average Revenue rise of 50.46%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 33 other companies have achieved higher Revenue growth. While Krystal Biotech Inc ' s Revenue rise of 30.21% ranks overall at the positon no. 1747 in the third quarter 2026.


KRYS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 30.21 %
2nd Quarter June 24.14 %
1st Quarter March 31.96 %
FY   -

Financial Statements
Krystal Biotech Inc 's third quarter 2026 Revenue $ 127.34 millions KRYS's Income Statement
Krystal Biotech Inc 's third quarter 2025 Revenue $ 97.80 millions Quarterly KRYS's Income Statement


KRYS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 6.81 %
2nd Quarter June 2.46 %
1st Quarter March 8.64 %
FY (Year on Year)   -


Back to KRYS Growth rate Comparisons >> Back to KRYS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #34
Healthcare Sector #278
Overall #1747

Revenue Y/Y Growth Statistics
High Average Low
116.09 % 50.46 % 22.63 %
(Jun 30 2025)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #34
Healthcare Sector #278
Overall #1747
Revenue Y/Y Growth Statistics
High Average Low
116.09 % 50.46 % 22.63 %
(Jun 30 2025)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Krystal Biotech Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
392.55 % 46.49 % -3.24 %
(Dec 31 2023)  


KRYS's III. Quarter Q/Q Revenue Comment
Krystal Biotech Inc achieved in the III. Quarter 2026 below company average Revenue increase of 6.81% quarter on quarter, to $ 127.34 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 1.83% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Krystal Biotech Inc 's Revenue growth quarter on quarter, overall rank is 1422.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #196
Overall #1422
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #196
Overall #1422
Revenue Q/Q Growth Statistics
High Average Low
392.55 % 46.49 % -3.24 %
(Dec 31 2023)  


KRYS's III. Quarter Q/Q Revenue Comment
Krystal Biotech Inc achieved in the III. Quarter 2026 below company average Revenue increase of 6.81% quarter on quarter, to $ 127.34 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.83% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Krystal Biotech Inc 's Revenue growth quarter on quarter, overall rank is 1422.


Krystal Biotech Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 470.03
Y / Y Revenue Growth (TTM) 25.96 %
Year on Year Revenue Growth Overall Ranking # 147
Seqeuential Revenue Change (TTM) 6.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 1754


Cumulative Revenue growth Comment
Although Krystal Biotech Inc 's Annual Revenue growth year on year were below company's average 50.46% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 25.96% year on year, from 22.63% in Jun 30 2026.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 147.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 34
Healthcare Sector # 44
Overall # 147

Revenue TTM Y/Y Growth Statistics
High Average Low
116.09 %
 50.46 %
22.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 279
S&P 500 # 1754
Cumulative Revenue growth Comment
Although Krystal Biotech Inc 's Annual Revenue growth year on year were below company's average 50.46% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 25.96% year on year, from 22.63% in Jun 30 2026.

In the Healthcare sector 43 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 19 to 147.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 34
Healthcare Sector # 44
Overall # 147

Revenue TTM Y/Y Growth Statistics
High Average Low
116.09 %
50.46 %
22.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 34
Sector # 279
S&P 500 # 1754




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KRYS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions


About Krystal Biotech Inc Revenue Growth Rates (KRYS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Krystal Biotech Inc (CIK 1711279).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001711279-26-000071
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Krystal Biotech Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.